Back HIV/AIDS

HIV / AIDS

ICAAC 2014: NRTI BMS-986001 Safe and Effective, but Associated with Resistance

BMS-986001, an experimental HIV nucleoside reverse transcriptase inhibitor, was shown to be as effective as tenofovir with less bone loss, but more people who took it developed resistance, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC. Bristol-Myers Squibb has announced it will end its development of the drug.

alt

ICAAC 2014: PK Study Shows Feasibility of Long-acting Integrase Inhibitor Cabotegravir

A pharmacokinetic (PK) analysis presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC, confirmed that the long-acting HIV integrase inhibitor cabotegravir (formerly GSK1265744) reaches adequate target levels in the blood, setting the stage for efficacy trials for HIV treatment and pre-exposure prophylaxis (PrEP).

alt

ICAAC 2014: Sangamo Provides Update on Gene Therapy to Protect T-cells From HIV

Several people with HIV whose CD4 T-cells were modified to make them resistant to viral entry have maintain low-level viral load after interrupting antiretroviral therapy (ART), with 1 individual having HIV RNA <1000 copies/mL for more than a year, according to a presentation at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.

alt

Coverage of the Interscience Conference on Antimicrobial Agents and Chemotherapy

HIVandHepatitis.com coverage of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014), September 5-9, in Washington, DC.

Conference highlights include experimental antiretroviral therapies for HIV, interferon-free treatment for hepatitis C, and news about other infectious diseases including tuberculosis, HPV, influenza, and Ebola virus.

Full listing of coverage by topic

ICAAC 2014 website

9/8/14

alt

Maraviroc Dose May Be Too Low for Many African-American People with HIV

A standard dose of the CCR5 antagonist maraviroc (Selzentry) may not be effective for many black people with HIV due to a genetic variation which increases production of a cytochrome P450 protein that speeds up processing of the drug, according to a study published in the August 12 advance edition of Drug Metabolism and Disposition.

alt

ICAAC 2014: New Tenofovir Alafenamide Combo Pill Has Less Effect on Kidneys and Bones

An experimental single-tablet regimen containing a new version of tenofovir (tenofovir alafenamide or TAF) and the HIV protease inhibitor darunavir (Prezista) worked as well as a similar regimen containing the older tenofovir disoproxil fumarate (TDF) formulation,but it had less detrimental effects on kidney function and bone density, according to a study presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.

alt

AIDS 2014: Most Gay Men Who Don’t Use Condoms Attempt to Reduce HIV Risk

Three-quarters of Australian gay and bisexual men who report unprotected anal intercourse with casual male partners say that they often or always employ some sort of risk reduction strategy with those partners, according to a report at the 20th International AIDS Conference in Melbourne. Many men attempt to select partners who they believe have the same HIV status as themselves (serosorting), a significant proportion use condoms most but not all of the time, and smaller numbers practice "strategic positioning" or withdrawal before ejaculation.

alt